Biogen Amevive Pre-Launch Work May Blunt Early Impact Of Formularies
Executive Summary
The large pool of unsatisfied psoriasis patients means that the early uptake of Biogen's Amevive will not hinge on reimbursement issues, the company maintained during a July 18 conference call
You may also be interested in...
Biogen Amevive Physician Reimbursement Guaranteed For Insurance Denials
Biogen will encourage physician uptake of the psoriasis biologic Amevive by guaranteeing reimbursement in cases where insurance coverage is anticipated but later denied
Biogen Amevive Physician Reimbursement Guaranteed For Insurance Denials
Biogen will encourage physician uptake of the psoriasis biologic Amevive by guaranteeing reimbursement in cases where insurance coverage is anticipated but later denied
Biogen Amevive Marketing Focus Will Be Duration Of Antipsoriatic Response
Biogen will distinguish Amevive in the psoriasis market by emphasizing the biologic's duration of response following FDA approval Jan. 30